论文部分内容阅读
目的观察米力农注射液治疗顽固性心衰患者的临床疗效。方法对68例经常规抗心衰治疗无好转的顽固性心衰患者,随机分为治疗组38例:应用米力农注射液2支加入氯化钠注射液100ml中静脉滴注,1次/d,7d为一疗程,原用药不变。对照组30例:除未用米力农注射液外,其余治疗同治疗组。结果治疗组血流动力学各项参数表明,无论心脏收缩功能及舒张功能均有明显好转,左室舒张末内径缩小,左室射血分数提高,与对照组对比差异有统计学意义(P<0.05)。结论米力农作为新一代治疗顽固性心衰的药物,可取得近期明显效果,使用安全。
Objective To observe the clinical effect of Milrinone injection in patients with refractory heart failure. Methods Sixty-eight patients with refractory heart failure who did not improve by conventional anti-heart failure treatment were randomly divided into treatment group (38 cases): two doses of Milrinone plus sodium chloride injection (100ml) d, 7d for a course of treatment, the original drug unchanged. Control group of 30 patients: except not with milrinone injection, the rest of the treatment with the treatment group. Results The parameters of hemodynamics in the treatment group showed that the systolic and diastolic functions were significantly improved, the diastolic diameter of the left ventricle was reduced and the left ventricular ejection fraction was increased, the difference was statistically significant compared with the control group (P < 0.05). Conclusion Milrinone as a new generation of refractory heart failure drugs, can achieve the recent significant results, the use of safety.